Invest In MJ Charts:

Latest News Release on Organigram

Organigram Announces Issuance of Stock Options

MONCTON, NEW BRUNSWICK--(Marketwired - March 14, 2017) - Organigram Holdings Inc. (TSX VENTURE:OGI)(OTCQB:OGRMF) ("Organigram" or the "Company") announces that it has issued an aggregate of 1,500,000 incentive stock options to Greg Engel, a director of the Company and the Company's Chief Executive Officer, at an exercise price of $2.36 per share.  
Read Full Press Release

OrganiGram Announces Closing of Financing and 70% Sales Growth

MONCTON, NEW BRUNSWICK--(Marketwired - Nov. 30, 2015) - THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.

OrganiGram Holdings Inc. (TSX VENTURE:OGI) (OTCQX:OGRMF) (the "Company") is pleased to announce the closing of its non-brokered private placement of securities for gross proceeds of $5,729,999.68 (the "Financing").

The Company has issued an aggregate of 3,009,612 units ("Units") at a price of $1.04 per Unit for gross proceeds of $3,129,999.48. Each Unit consists of one Common share of the Company (a "Common Share"), and one-half of a share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will be exercisable into one additional Common Share (a "Warrant Share") of the Company at $1.40 per Warrant Share for a period of eighteen (18) months from the date of closing of the Financing. The Company intends to use the proceeds from the Offering for accelerated facility expansion and general working capital purposes... Read Full Press Release.

OrganiGram Holdings Inc.: Response to filing of Lawsuit by Marijuana For Trauma

OrganiGram Holdings Inc. (TSX VENTURE:OGI)(OGRMF) (the "Company")wishes to issue the following statement regarding this morning's announcement of a lawsuit filed against OrganiGram Holdings and OrganiGram Inc. by Marijuana for Trauma (MFT).

"While we are aware of the lawsuit filed by MFT, the details, as outlined in their national press release are inaccurate and defamatory. At no time was there ever an agreement with Organigram Holdings or OrganiGram Inc. with MFT in relation to the development of Trauma Healing Centers (THC) across the country. As well, we believe this lawsuit to be an attempt to embarrass the principals and the company as well as to deflect from the failure of MFT to fulfill an employment contract they signed with THC in 2014. We intend to defend these false claims vigorously in court and intend to file a counter claim against MFT. As well, this lawsuit has given us the opportunity to fully understand that MFT has not been operating openly and honestly. As a result of their news release we have discovered that MFT has been signing exclusive deals with a number of licensed medical marijuana producers (LPs) across the country and not fulfilling those contractual obligations. At the end of the day we look forward to the truth being unveiled."

About OrganiGram Holdings

Organigram Holdings Inc. is a TSX Venture Exchange listed company who's wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. At OrganiGram, our mission is to be the leading producer of organically grown medical marijuana. By combining advanced technologies and proven methods, we assure a secure and regulated source of medical marijuana for patients and doctors in Canada that requires no irradiation or cold pasteurization. All of our products are lab tested prior to packaging and are manufactured under strict controls and in conformance with the Good Production Practices of the MMPR as well as the security directives as defined by the Office of Controlled Substances - See more at: https://www.organigram.ca.

April 29, 2015

OrganiGram Holdings Inc. (TSX-V: OGI) (OTC US:OGRMF) (the “Company”) is pleased to announce that it has received two Letters of Interest (LOIs) which will provide long-term debt totaling $5,000,000. The Credit Facilities significantly strengthen OGI’s financial position in a manner that is non-dilutive to shareholders. 

The Company will be utilizing the capital injection to continue the development of its medical marijuana facility in Moncton, NB.

Organigram’s President, Mr. Rogers states, “We are very pleased to have negotiated a non-dilutive form of financing for Organigram. These LOIs, totaling $5,000,000, will provide the necessary capital required to further accelerate our growth strategy.”

Organigram has experienced a significant increase in patient registrations over the past few months and as such, is very pleased to have the capital to continue to accelerate their client acquisition strategies. The Company is currently awaiting Health Canada inspection of 4 newly completed growing rooms, which are expected to come online by the end of June 2015.

Additionally, the Company has signed a multi-year agreement with Deloitte LLP (“Deloitte”) to provide audit services. Deloitte is the largest Canadian provider of professional financial services and the lead accounting firm in the medical marijuana industry, representing numerous other Licensed Producers. Deloitte maintains in-house expertise in the field and are members of the Canadian National Medical Marijuana Association.

To view the entire news release or for further information on OrganiGram, please visit www.organigram.ca.

Regards,

Brett Allan
Director of IR & Business Development
OrganiGram Holdings Inc.

T: 416-907-4148
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

 -----------------------------------------------------

March 16, 2015

OrganiGram Holdings Inc. (TSX-V: OGI) (OTC US:OGRMF) (the “Company”) is pleased to announce that is has successfully completed an initial harvest from one of the three newly constructed grow rooms that were approved by Health Canada in December 2014.  As a result, the Company has significantly increased production, available strains, and has been able to increase its registered patient list by 250%. It is anticipated that this growth will continue over the coming weeks with a further doubling of our active patients.

On March 4th, the Company completed a harvest of approximately 95lbs of saleable product. The Company will soon be completing two harvests of a similar size and expects to do so once every 5 weeks with the existing facility. With the anticipated upcoming approval of 4 additional grow rooms; the Company expects to increase the regularity of harvest to once every 2 weeks and the associated number of customers to be supplied with our product.

“This is a pivotal point for Organigram and the entire team has worked very hard to help get us here. We are extremely happy to be able to increase sales, reduce the wait list and have a larger selection of product availability for our patients. We are eagerly anticipating the completion of another 4 grow rooms which should be coming online in the next few weeks. I would like to thank all of our patients for their continued support and we look forward to continuing to provide the best quality product and customer service available.” said Denis Arsenault, Chairman & CEO

To view the entire news release or for further information on OrganiGram, please visit www.organigram.ca.

-----------------------------------------------------

OrganiGram Provides Shareholder Update

Moncton, N.B. January 20, 2015 – OrganiGram Holdings Inc. (TSX-V: OGI) (OTC US:OGRMF) (the “Company”) is pleased to provide an update to shareholders while reviewing milestones of 2014 and looking at the growth and goals of 2015.

Since the inception of Organigram in April 2014, the Company has been growing and developing at a very fast pace. Through this growth, there have been some tremendous achievements, which include receiving our organic certification, producing our first crops, listing of shares on the TSX Venture and completing three phases of construction. Organigram is excited to capitalize on these achievements and execute on our business plan.

Moving forward, our shareholders, patients and partners will begin to see the results from the foundation laid in 2014. To date, the company has been extremely focused on expanding the production facility while, at the same time, working to increase production levels. These efforts will begin to provide significant product to the market in March of this year. Thereafter, the utilization of our existing rooms and rooms under construction will ensure that Organigram is poised to meet our financial goals in 2015.

Organigram would like to take this opportunity to congratulate Trauma Healing Centers on the opening of their first clinic, in Halifax, NS. Organigram is proud to be partnered with Trauma Healing Centers on research initiatives to assist our Veterans and others suffering with PTSD.

Organigram’s CEO, Denis Arsenault states, “Over the past few months, Organigram has moved into a “best in class” manufacturing facility. Our processes and systems have been developed to a point where we produce high quality products, in an organic form, which has and will continue to exceed the requirements of our clients. While we continue to evolve and improve, our facility will begin to supply the market with an established source of product on a consistent basis. We have a superior management team in place that is not only focused on supply but also quality, efficiency and product development.  The results of our efforts will not only be very profitable for the company and shareholders but most importantly will provide a rapidly increasing client base with a medicinal product that assists in a much-improved quality of life for many. The developments of the next few weeks and months will be both exciting and fruitful for our company.”

About Organigram Holdings Inc.

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada.  Organigram is focused on producing the highest quality, condition specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Marihuana for Medical Purposes Regulations.

On behalf of the board of directors,

Denis Arsenault
Director and CEO
Organigram Holdings Inc.

For further information please visit www.organigram.ca or contact:

Brett Allan
Dir. Of Investor Relations
OrganiGram Holdings Inc.
(416) 907-4148

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities — that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com).  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.  The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Past News and Press Releases:

December 22, 2014 - OrganiGram Obtains $2.5M Loan From Farm Credit Canada & Announces Closing of Equity Financing of $1.4M